Contribe ApS er et SaaS værktøj som øger virksomheders kommercielle udbytte af donationer. Vi gør det nemmere, mere transparent og mere effektivt for virksomheder, at dokumentere, og kommunikere de resultater der opna?s i donations- og leverandørsamarbejder. Vores teknologi sikrer effektiv datavalidering og effektiviserer manuelt arbejde, sa?ledes virksomhederne spares for markante administrative byrder. Vores værktøj, besta?ende af dels et management tool for nem projektha?ndtering i virksomheden dels en række plugins til nemt at integrere positiv impact i intern- og ekstern kommunikation, hjælper virksomheder til at hjælpe vores planet og samtidig opna? en kommerciel og økonomisk fordel. Vi hjælper parterne til nemt at finde hinanden og indga? partnerskaber. Vores værktøj visualiserer alt projektdata pa? e?t sted og ved brug af vores plugins bliver bæredygtige samarbejder en del af enhver online købsprocess, hvorved vi kan effektivisere marketing og kommunikationsindsatser betydeligt samtidig med at kanalisere midler ud til gode og vigtige formål. Kort fortalt hjælper Contribe virksomheder med at drive god forretning på at gøre gode ting.

Too Great To Cancel er en platform, hvor rejser som er blevet anmeldt til et forsikringsselskab videresælges. Indtil nu er disse rejser blevet afbestilt og tabet er realiseret hos forsikringsselskabet. Too Great To Cancel videresælger disse rejser for at undgå det nuværende spild af rejsens værdi.

In the pursuit of a scalable and fault-tolerant quantum computing paradigm, TopQC2X presents a comprehensive research initiative that bridges the realms of theory, physical implementation, and practical applications. Focusing on topological quantum computation (TQC), the project leverages the unique strengths of the Centre of Quantum Mathematics (QM) at the University of Southern Denmark (SDU) and the Quantum Physics and Information Technology (QPIT) group at the Technical University of Denmark (DTU). QM will develop and apply new topological tools for quantum computation including 1) surface codes tailored for the photonic platform via GKP states and 2) topological quantum field theories (TQFTs) based on the Andersen-Kashaev TQFT. The physical implementation, led by QPIT at DTU, focuses on realizing such schemes on photonic platforms for enhanced error correction in the setting of continuous variable quantum computation (CVQC). An integral component of TopQC2X is the development of quantum algorithms and software tailored to TQC, enabling the utilization of TQFT language for algorithm design. Further, TopQC2X will grow applications across green energy, financial services, climate modeling, and signal processing/compressed sensing with industry and research leaders such as Ørsted, Jyske Bank, DMI and AAU. Quantum algorithms are developed to address industry-specific challenges, offering solutions that exploit the power of TQC across different industry sectors.

Schizophrenia is among others characterized by hypofrontality. Hypofrontality is the reduced utilization of glucose and decreased blood flow in the prefrontal cortex and appears to be linked to the debilitating cognitive deficits and negative symptoms that are reported in patients with schizophrenia. The currently available antipsychotics do not reduce hypofrontality, they may actually worsen it, which is likely the reason that they are ineffective in ameliorating the cognitive deficits and negative symptoms in patients with schizophrenia. Antagonists of NMDA (N-methyl-D-aspartate) receptors, such as PCP, ketamine and MK-801 are known to induce hypofrontality. In one of Gabather's preclinical studies, GT-002 proved able to counteract effects of MK-801. This suggests that, unlike antipsychotics, GT-002 might be able to reduce hypofrontality, and thus also may ameliorate cognitive deficits and negative symptoms in patients with schizophrenia. Validating this observation will be a major breakthrough in the treatment of schizophrenia. The current project has been developed to take the first necessary step in this direction, by investigating the effects of two doses of GT-002 in patients with schizophrenia and healthy controls.